BRPI0413728A - muteìnas de lipocalina da lágrima - Google Patents

muteìnas de lipocalina da lágrima

Info

Publication number
BRPI0413728A
BRPI0413728A BRPI0413728-0A BRPI0413728A BRPI0413728A BR PI0413728 A BRPI0413728 A BR PI0413728A BR PI0413728 A BRPI0413728 A BR PI0413728A BR PI0413728 A BRPI0413728 A BR PI0413728A
Authority
BR
Brazil
Prior art keywords
mutein
tear lipocalin
lipocalin muteins
lipocalin
relates
Prior art date
Application number
BRPI0413728-0A
Other languages
English (en)
Inventor
Arne Skerra
Steffen Schlehuber
Original Assignee
Pieris Proteolab Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Proteolab Ag filed Critical Pieris Proteolab Ag
Publication of BRPI0413728A publication Critical patent/BRPI0413728A/pt
Publication of BRPI0413728B1 publication Critical patent/BRPI0413728B1/pt
Publication of BRPI0413728B8 publication Critical patent/BRPI0413728B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MUTEìNAS DE LIPOCALINA DA LáGRIMA". A presente invenção refere-se às novas muteínas derivadas de lipocalina da lágrima ou um homólogo da mesma. Especificamente, a invenção refere-se a uma muteína da lágrima humana. A invenção também se refere a uma molécula de ácido nucléico correspondente codificando tal muteína e a um processo para sua geração. A invenção se refere, adicionalmente, a um método para produzir tal muteína. Finalmente, a invenção é dirigida a uma composição farmacêutica compreendendo tal muteína de lipocalina, bem como aos vários usos da muteína.
BRPI0413728A 2003-08-25 2004-08-24 muteína da lipocalina da lágrima humana, métodos para geração e para produção de muteína, composição farmacêutica e uso de muteína BRPI0413728B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2003/009404 WO2005019255A1 (en) 2003-08-25 2003-08-25 Muteins of tear lipocalin
PCT/EP2004/009447 WO2005019256A2 (en) 2003-08-25 2004-08-24 Muteins of tear lipocalin

Publications (3)

Publication Number Publication Date
BRPI0413728A true BRPI0413728A (pt) 2006-10-24
BRPI0413728B1 BRPI0413728B1 (pt) 2017-05-23
BRPI0413728B8 BRPI0413728B8 (pt) 2021-05-25

Family

ID=34203142

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413728A BRPI0413728B8 (pt) 2003-08-25 2004-08-24 muteína da lipocalina da lágrima humana, métodos para geração e para produção de muteína, composição farmacêutica e uso de muteína

Country Status (13)

Country Link
US (2) US7585940B2 (pt)
EP (1) EP1660528B1 (pt)
JP (1) JP4856543B2 (pt)
CN (1) CN1871256B (pt)
AT (1) ATE446313T1 (pt)
AU (2) AU2003275958A1 (pt)
BR (1) BRPI0413728B8 (pt)
CA (1) CA2536491C (pt)
DE (1) DE602004023725D1 (pt)
DK (1) DK1660528T3 (pt)
HK (1) HK1084404A1 (pt)
SG (1) SG131109A1 (pt)
WO (2) WO2005019255A1 (pt)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003275958A1 (en) * 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
US7611847B2 (en) 2005-06-01 2009-11-03 Agency For Science, Technology And Research Method for identifying an intestinal phenotype
EP1989529A4 (en) 2006-02-13 2010-09-01 Agency Science Tech & Res PROCESS FOR PROCESSING A BIOLOGICAL AND / OR CHEMICAL SAMPLE
EP2004328B1 (en) 2006-03-09 2014-06-04 Agency for Science, Technology and Research Method for performing a reaction in a droplet
EP1996613B1 (en) 2006-03-20 2014-04-30 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
ES2354653T3 (es) * 2006-08-01 2011-03-16 Pieris Ag Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas.
KR101516023B1 (ko) * 2006-08-01 2015-04-30 피어이스 에이지 눈물 리포칼린 돌연변이 단백질 및 이를 얻는 방법
WO2008063135A1 (en) 2006-11-24 2008-05-29 Agency For Science, Technology And Research Apparatus for processing a sample in a liquid droplet and method of using the same
US9874501B2 (en) 2006-11-24 2018-01-23 Curiox Biosystems Pte Ltd. Use of chemically patterned substrate for liquid handling, chemical and biological reactions
JP2010523652A (ja) 2007-04-13 2010-07-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 腫瘍発生を制御する方法および腫瘍発生のリスクを診断する方法
JP2011504462A (ja) 2007-11-02 2011-02-10 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 腫瘍の予防および治療のための方法および化合物
WO2013114217A1 (en) 2012-02-05 2013-08-08 Curiox Biosystems Pte Ltd. Array plates and methods for making and using same
US10725020B2 (en) 2007-11-14 2020-07-28 Curiox Biosystems Pte Ltd. High throughput miniaturized assay system and methods
EP2222709B1 (en) 2007-11-30 2016-11-23 Glaxo Group Limited Antigen-binding constructs
US20090274623A1 (en) * 2008-01-30 2009-11-05 General Electric Company In vivo imaging agents for met receptor tyrosine kinase
CN106986926A (zh) * 2008-01-30 2017-07-28 皮里斯股份公司 具有对人c‑met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
US9051568B2 (en) 2008-04-25 2015-06-09 Rutgers, The State University Of New Jersey Anti-sense microrna expression vectors
PE20091882A1 (es) 2008-05-06 2009-12-24 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
WO2009136867A1 (en) 2008-05-06 2009-11-12 Agency For Science, Technology And Research Method of effecting de-differentiation of a cell
EP3381933B1 (en) 2008-06-24 2020-06-03 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
JP2010074915A (ja) * 2008-09-17 2010-04-02 Jtekt Corp モータ制御装置及び電動パワーステアリング装置
US8716420B2 (en) 2008-10-13 2014-05-06 Agency For Science, Technology And Research Amphiphilic polymers and nanocrystals coated therewith
ATE523603T1 (de) 2008-11-21 2011-09-15 Chimera Biotec Gmbh Konjugatkomplexe zum analytnachweis
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
CA2753332A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
CA2753263A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
US8784752B2 (en) 2009-04-17 2014-07-22 Curiox Biosystems Pte Ltd Use of chemically patterned substrate for liquid handling, chemical and biological reactions
CN102549427A (zh) 2009-07-07 2012-07-04 新加坡科技研究局 鉴定结合配偶体对的方法
SG177763A1 (en) 2009-07-28 2012-03-29 Hoffmann La Roche Non-invasive in vivo optical imaging method
WO2011015634A2 (en) * 2009-08-05 2011-02-10 Pieris Ag Controlled release formulations of lipocalin muteins
EP2510357B1 (en) 2009-12-07 2016-03-30 Pieris AG Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
US9689801B2 (en) 2009-12-22 2017-06-27 Agency For Science, Technology And Research SERS-based analyte detection
KR20130028055A (ko) 2010-01-28 2013-03-18 글락소 그룹 리미티드 Ｃｄ １２７ 결합 단백질
KR101341640B1 (ko) * 2010-02-05 2013-12-16 한국전자통신연구원 단백질 미세 구조 분석 방법 및 단백질 미세 구조 분석용 어레이
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
CN107098958B (zh) 2010-03-26 2021-11-05 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
WO2011138462A1 (en) 2010-05-07 2011-11-10 F. Hoffmann-La Roche Ag Diagnostic method for the detection of cells ex vivo
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
ES2729652T3 (es) 2010-06-08 2019-11-05 Pieris Pharmaceuticals Gmbh Muteína de lipocalina lacrimal unidas a IL-4R alpha
US9878328B2 (en) 2010-07-23 2018-01-30 Curiox Biosystems Pte Ltd. Apparatus and method for multiple reactions in small volumes
CA2808392C (en) 2010-08-16 2020-03-10 Pieris Ag Binding proteins for hepcidin
EP2614073B1 (en) 2010-09-07 2018-03-14 Technische Universität München Recombinant bacterial lipocalin blc and uses thereof
CA2810668A1 (en) * 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
EP2640740B1 (en) 2010-11-15 2017-03-15 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
PT2643352T (pt) 2010-11-23 2018-08-01 Glaxo Group Ltd Proteínas de ligação a antigénio para a oncostatina m (osm)
WO2012069557A1 (en) 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
EP2646552B1 (en) 2010-12-02 2017-07-05 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for ctla-4
WO2012136685A1 (en) 2011-04-04 2012-10-11 Pieris Ag Methods and compositions for anti-vegf and anti-c-met therapy
RU2016147206A (ru) 2011-04-15 2018-10-19 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
LT3415531T (lt) 2011-05-27 2023-09-25 Glaxo Group Limited Bcma (cd269/tnfrsf17) – surišantys baltymai
WO2013048986A1 (en) 2011-09-26 2013-04-04 Knoa Software, Inc. Method, system and program product for allocation and/or prioritization of electronic resources
EP2771351B1 (en) 2011-10-28 2017-06-14 Patrys Limited Pat-lm1 epitopes and methods for using same
DK2791684T3 (da) 2011-12-12 2017-11-27 Pieris Pharmaceuticals Gmbh Fremgangsmåder til forebyggelse eller behandling af forstyrrelser ved forøgelse af biotilgængeligheden af jern og relateret farmaceutisk formulering
SG10201604566QA (en) 2011-12-13 2016-07-28 Pieris Ag Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
SG11201403714TA (en) 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
EP2802341B1 (en) 2012-01-09 2019-03-06 Pieris Pharmaceuticals GmbH Methods for preventing, treating or diagnosing disorders
US9758554B2 (en) 2012-01-31 2017-09-12 Technische Universitaet Muenchen Muteins of α1m lipocalin and method of production therefor
RS60583B1 (sr) 2012-02-13 2020-08-31 Agency Science Tech & Res Ljudska monoklonalna antitela koja vrše neutralizaciju il-ss
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9522940B2 (en) * 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
WO2013189521A1 (en) 2012-06-19 2013-12-27 Waclawczyk Simon Method of generating cells of hepatocyte phenotype
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
AU2013343667A1 (en) 2012-11-08 2015-04-02 F. Hoffmann-La Roche Ag HER3 antigen binding proteins binding to the beta-hairpin of HER3
EP2920202B1 (en) 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
RU2015142437A (ru) * 2013-03-14 2017-04-27 Дайити Санкио Ко., Лтд Новые связывающие белки для pcsk9
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
US9557318B2 (en) 2013-07-09 2017-01-31 Curiox Biosystems Pte Ltd. Array plates for washing samples
WO2015051199A2 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
US9803008B2 (en) 2013-11-28 2017-10-31 Csl Limited Method of treating diabetic nephropathy by administering antibodies to vascular endothelial growth factor B (VEGF-B)
JP6553618B2 (ja) 2013-12-18 2019-07-31 シーエスエル リミティド 創傷を治療する方法
DK3087098T3 (da) 2013-12-24 2020-06-08 Janssen Pharmaceutica Nv Anti-Vista-antistoffer og -fragmenter
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
US10927154B2 (en) 2014-01-13 2021-02-23 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
LU92409B1 (en) 2014-03-21 2015-09-22 Philipps Universit T Marburg Means and methods for itaconic acid production
WO2015177175A2 (en) 2014-05-22 2015-11-26 Pieris Ag Novel specific-binding polypeptides and uses thereof
CA2951885C (en) 2014-06-11 2023-07-04 Kathy A. Green Use of vista agonists and antagonists to suppress or enhance humoral immunity
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
EP3489256B1 (en) 2014-11-14 2021-03-17 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
WO2016113203A1 (en) 2015-01-12 2016-07-21 Pieris Ag Engineered t cells and uses therefor
AU2016212087B2 (en) 2015-01-28 2019-11-07 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
EP3064507A1 (en) 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
CA2980839A1 (en) * 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
US10865250B2 (en) 2015-05-04 2020-12-15 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
CA2982034A1 (en) 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
HRP20230145T1 (hr) 2015-05-18 2023-04-28 Pieris Pharmaceuticals Gmbh Fuzijski polipeptid protiv raka
US10545139B2 (en) 2015-06-16 2020-01-28 Curiox Biosystems Pte Ltd. Methods and devices for performing biological assays using magnetic components
US11009509B2 (en) 2015-06-24 2021-05-18 Janssen Pharmaceutica Nv Anti-VISTA antibodies and fragments
EP3115066A1 (en) 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins
EA201890198A1 (ru) 2015-07-15 2018-07-31 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Новые белки, специфичные в отношении lag-3
AU2016306597A1 (en) 2015-08-07 2018-02-22 Pieris Pharmaceuticals Gmbh Novel fusion polypeptide specific for LAG-3 and PD-1
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MA43017A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
EP3356411B1 (en) 2015-10-02 2021-06-30 F. Hoffmann-La Roche AG Bispecific antibodies specific for pd1 and tim3
EP3359568B1 (en) 2015-10-07 2022-03-09 F. Hoffmann-La Roche AG Bispecific antibodies with tetravalency for a costimulatory tnf receptor
CN108699162A (zh) 2015-11-30 2018-10-23 皮里斯澳大利亚有限公司 新型抗血管生成融合多肽
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
TW202216201A (zh) 2016-02-12 2022-05-01 比利時商楊森製藥公司 抗vista抗體及片段、其用途及鑑定其之方法
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
CN117562992A (zh) 2016-04-15 2024-02-20 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
CN109071652B (zh) 2016-05-11 2022-09-23 豪夫迈·罗氏有限公司 包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
JP2020501508A (ja) 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
AU2017331739A1 (en) 2016-09-23 2019-03-07 Csl Limited Coagulation factor binding proteins and uses thereof
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
TWI829628B (zh) 2016-12-19 2024-01-21 瑞士商赫孚孟拉羅股份公司 與靶向4-1bb (cd137)促效劑併用之組合療法
AU2017384126A1 (en) 2016-12-20 2019-05-02 F. Hoffmann-La Roche Ag Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
RU2019123613A (ru) 2017-01-03 2021-02-05 Ф. Хоффманн-Ля Рош Аг Биспецифические антигенсвязывающие молекулы, содержащие антитело к4-1вв, клон 20н4.9
JP7225116B2 (ja) 2017-01-18 2023-02-20 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン
WO2018134279A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
EP3601346A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
JP7196094B2 (ja) 2017-03-29 2022-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
AU2018247796A1 (en) 2017-04-04 2019-08-29 F. Hoffmann-La Roche Ag Novel bispecific antigen binding molecules capable of specific binding to CD40 and to FAP
CN110506059B (zh) 2017-04-05 2023-01-17 豪夫迈·罗氏有限公司 特异性结合pd1和lag3的双特异性抗体
CN110709979B (zh) 2017-04-05 2024-04-09 科睿思生物科技(私人)有限公司 用于清洗阵列板上的样品的方法、设备和装置
US11466073B2 (en) 2017-10-18 2022-10-11 Csl Limited Human serum albumin variants and uses thereof
JP2021500902A (ja) 2017-11-01 2021-01-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
AU2018359506A1 (en) 2017-11-01 2020-04-23 F. Hoffmann-La Roche Ag Combination therapy with targeted OX40 agonists
CN111182944B (zh) 2017-11-01 2022-11-22 豪夫迈·罗氏有限公司 双特异性2+1 Contorsbody
KR20200093562A (ko) 2017-11-29 2020-08-05 씨에스엘 리미티드 허혈-재관류 손상을 치료 또는 예방하는 방법
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
CA3090232A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
EP3765489A1 (en) 2018-03-13 2021-01-20 F. Hoffmann-La Roche AG Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
PE20210652A1 (es) 2018-04-13 2021-03-26 Hoffmann La Roche Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
WO2019243564A1 (en) 2018-06-21 2019-12-26 Technische Universitaet Muenchen Hepatitis b and/or hepatitis d-permissive cells and animals
CN112424228A (zh) 2018-07-04 2021-02-26 豪夫迈·罗氏有限公司 新型双特异性激动性4-1bb抗原结合分子
EP3830120B9 (en) 2018-07-31 2023-08-30 Pieris Pharmaceuticals GmbH Novel fusion protein specific for cd137 and pd-l1
WO2020070035A1 (en) 2018-10-01 2020-04-09 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules with trivalent binding to cd40
UA126188C2 (uk) 2018-10-01 2022-08-25 Ф. Хоффманн-Ля Рош Аг Біспецифічна антигензв'язувальна молекула, яка містить домен зв'язування з fap та домен зв'язування з сd40
AR117728A1 (es) 2018-12-21 2021-08-25 Hoffmann La Roche Moléculas superagonistas de unión al antígeno cd28 con diana tumoral
WO2020127618A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted agonistic cd28 antigen binding molecules
JP7476219B2 (ja) 2019-02-26 2024-04-30 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
KR20210146934A (ko) 2019-03-29 2021-12-06 아스트라제네카 에이비이 천식 치료를 위한 리포칼린 뮤테인
WO2020201038A1 (en) 2019-03-29 2020-10-08 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
EP3952996A1 (en) 2019-04-12 2022-02-16 F. Hoffmann-La Roche AG Bispecific antigen binding molecules comprising lipocalin muteins
JP2022538075A (ja) 2019-06-26 2022-08-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体結合ｃｅａ及び４－１ｂｂｌの融合
JP7354306B2 (ja) 2019-06-27 2023-10-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
US20240166763A1 (en) 2019-11-04 2024-05-23 Pieris Pharmaceuticals Gmbh Her2/4-1bb bispecific fusion proteins for the treatment of cancer
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
EP4161957A1 (en) 2020-06-05 2023-04-12 Pieris Pharmaceuticals GmbH Multimeric immunomodulator targeting 4-1bb
US20220017637A1 (en) 2020-06-23 2022-01-20 Hoffmann-La Roche Inc. Agonistic cd28 antigen binding molecules targeting her2
EP4172203A1 (en) 2020-06-25 2023-05-03 F. Hoffmann-La Roche AG Anti-cd3/anti-cd28 bispecific antigen binding molecules
EP4244254A1 (en) 2020-11-16 2023-09-20 F. Hoffmann-La Roche AG Combination therapy with fap-targeted cd40 agonists
JP2023553703A (ja) 2020-12-18 2023-12-25 アストラゼネカ・アクチエボラーグ 喘息の治療のためのリポカリンムテイン乾燥粉末製剤
WO2022148732A1 (en) 2021-01-06 2022-07-14 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
CA3209479A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
EP4313099A2 (en) 2021-03-23 2024-02-07 Pieris Pharmaceuticals GmbH Her2/4-1bb bispecific fusion proteins for the treatment of cancer
KR20230165917A (ko) 2021-04-08 2023-12-05 피어이스 파마슈티컬즈 게엠베하 결합 조직 성장 인자(ctgf)에 특이적인 신규 리포칼린 뮤테인
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
TW202309078A (zh) 2021-07-02 2023-03-01 美商建南德克公司 治療癌症之方法及組成物
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
TW202334203A (zh) 2021-11-19 2023-09-01 德商皮里斯製藥有限公司 新穎的ox40及pd-l1特異性融合蛋白
TW202340248A (zh) 2021-12-20 2023-10-16 瑞士商赫孚孟拉羅股份公司 促效性ｌｔｂｒ抗體及包含其之雙特異性抗體
WO2023186756A1 (en) 2022-03-28 2023-10-05 F. Hoffmann-La Roche Ag Interferon gamma variants and antigen binding molecules comprising these
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
WO2024056862A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
WO2024064713A1 (en) 2022-09-21 2024-03-28 Seagen Inc. Novel fusion protein specific for cd137 and cd228
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2152818A1 (en) 1992-12-31 1994-07-21 Jay P. Morgenstern Allergenic proteins and peptides from dog dander and uses therefor
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
DE19742706B4 (de) * 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US20030236188A1 (en) 2001-05-03 2003-12-25 Spytek Kimberly A. Novel human proteins, polynucleotides encoding them and methods of using the same
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
AU2003275958A1 (en) * 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin

Also Published As

Publication number Publication date
JP4856543B2 (ja) 2012-01-18
WO2005019256A2 (en) 2005-03-03
WO2005019255A1 (en) 2005-03-03
US7893208B2 (en) 2011-02-22
DK1660528T3 (da) 2010-01-04
CA2536491A1 (en) 2005-03-03
US20070224633A1 (en) 2007-09-27
JP2007531503A (ja) 2007-11-08
SG131109A1 (en) 2007-04-26
BRPI0413728B1 (pt) 2017-05-23
AU2004266846B2 (en) 2011-01-06
BRPI0413728B8 (pt) 2021-05-25
AU2003275958A1 (en) 2005-03-10
AU2004266846A1 (en) 2005-03-03
ATE446313T1 (de) 2009-11-15
DE602004023725D1 (de) 2009-12-03
EP1660528A2 (en) 2006-05-31
WO2005019256A3 (en) 2005-07-21
US20090325875A1 (en) 2009-12-31
WO2005019255A8 (en) 2005-05-26
CN1871256A (zh) 2006-11-29
HK1084404A1 (en) 2006-07-28
US7585940B2 (en) 2009-09-08
CN1871256B (zh) 2010-06-23
CA2536491C (en) 2013-12-24
EP1660528B1 (en) 2009-10-21

Similar Documents

Publication Publication Date Title
BRPI0413728A (pt) muteìnas de lipocalina da lágrima
HK1131167A1 (zh) 淚液脂質運載蛋白的突變蛋白及其獲得方法
HUP0500634A2 (hu) Anyagok és eljárások az idegszövet helyreállításának elősegítésére
DE60143292D1 (de) Varianten des menschlichen Koagulationsfaktors VII
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
DE60315847D1 (de) Varianten des menschliche koagulationsfaktors vii
ATE385419T1 (de) Dermatologische und kosmetische zusammensetzungen enthaltend ein furfurylderivat
PT1411908E (pt) Tratamento de infeccoes da unha com no
NO20031129D0 (no) Varianter av human koagulasjonsfaktor VII
SE0301653D0 (sv) Novel compounds
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
BR0311568A (pt) Método de tratamento de cabelo e uso de uma composição
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
NO20010940D0 (no) TAN-1057 derivater
BR0312197A (pt) Polissacarìdeo supersulfatado de baixo peso molecular
WO2005016371A8 (en) IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES
DE60104866D1 (de) Aminoalkenylbenzoyl-benzofurane oder benzothiophene, verfahren zur ihrer herstellung und sie enthaltende zubereitungen
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
WO2005034978A3 (en) MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF
DK1257538T3 (da) 9-alkylamino-1-nitroacridin-derivater
WO2004071383A3 (en) New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action
WO2005023767A3 (en) Diastereomers of 4-aryloxy-3-hydroxypiperidines

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/08/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF